Unlearn, developer of the first machine-learning platform that creates Digital Twins used to populate Intelligent Control Arms in clinical studies, today announced that Eisai, a leading global research and development-based pharmaceutical company, has joined the company's world-class syndicate of investors as part of its Series A extension along with Epic Ventures and Alumni Ventures Group. In April 2020, Unlearn announced Series A financing led by 8VC with participation from DCVC, DCVC Bio and Mubadala Capital Ventures. The extension brings the Series A total to $15 million.

Unlearn has developed the first machine learning (ML) platform for creating Intelligent Control Arms with Digital Twins through its proprietary DiGenesis™ process, allowing drug developers to dramatically improve clinical evidence and trial power, while lowering the risk of trial failure, thereby increasing confidence in clinical trial results. Unlearn is working with biopharmaceutical and medical device companies as well as regulators to ensure its methods meet the highest scientific and regulatory standards. CB Insights ranked Unlearn a Digital Health 150 company, designating Unlearn as one of the most innovative private digital health companies in the world in 2020.